Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. by Prendergast, A, Walker, A, Mulenga, V, Chintu, C, Gibb, D

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. by Walker, A, Mulenga, V, Sinyinza, F, Lishimpi, K, Nunn, A, Chintu, C, Gibb, D

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. by Walker, A, Mulenga, V, Ford, D, Kabamba, D, Sinyinza, F, Kankasa, C, Chintu, C, Gibb, D

Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children. by Walker, A, Ford, D, Mulenga, V, Thomason, M, Nunn, A, Chintu, C, Gibb, D, Bangsberg, DR

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. by Oudijk, J, McIlleron, H, Mulenga, V, Chintu, C, Merry, C, Walker, A, Cook, A, Gibb, D, Burger, D

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? by Fillekes, Q, Mulenga, V, Kabamba, D, Kankasa, C, Thomason, M, Cook, A, Chintu, C, Gibb, D, Walker, A, Burger, D

Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing by Mbisa, J, Gupta, R, Cane, P, Kabamba, D, Mulenga, V, Kalumbi, M, Chintu, C, Gibb, D, Walker, A, Pillay, D

Identification of the phenotypic, genotypic and fitness correlates of non-B subtype HIV-1 NRTI resistance through longitudinal analysis of children with virological failure in the... by Mbisa, J, Gupta, R, Cane, P, Kabamba, D, Mulenga, V, Kalumbi, M, Chintu, C, Gibb, D, Walker, A, Pillay, D

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. by L'homme, R, Kabamba, D, Ewings, F, Mulenga, V, Kankasa, C, Thomason, M, Walker, A, Chintu, C, Burger, D, Gibb, D

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. by Burger, D, Ewings, F, Kabamba, D, L'homme, R, Mulenga, V, Kankasa, C, Thomason, M, Gibb, D, Chintu, C, Walker, A

The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. by Mbisa, J, Gupta, R, Kabamba, D, Mulenga, V, Kalumbi, M, Chintu, C, Parry, C, Gibb, D, Walker, SA, Cane, P, Pillay, D

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. by Fillekes, Q, Mulenga, V, Kabamba, D, Kankasa, C, Thomason, M, Cook, A, Ferrier, A, Chintu, C, Walker, A, Gibb, D, Burger, D

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. by Gupta, R, Ford, D, Mulenga, V, Walker, A, Kabamba, D, Kalumbi, M, Grant, P, Ferrier, A, Pillay, D, Gibb, D, Chintu, C

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. by Chintu, C, Bhat, G, Walker, A, Mulenga, V, Sinyinza, F, Lishimpi, K, Farrelly, L, Kaganson, N, Zumla, A, Gillespie, S, Nunn, A, Gibb, D

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets by Bienczak, A, Denti, P, Cook, A, Wiesner, L, Mulenga, V, Kityo, C, Keketiinwa, A, Gibb, D, Burger, D, Walker, A, McIlleron, H

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. by Ryan, M, Griffin, S, Chitah, B, Walker, A, Mulenga, V, Kalolo, D, Hawkins, N, Merry, C, Barry, MG, Chintu, C, Sculpher, M, Gibb, D

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. by Mulenga, V, Ford, D, Walker, A, Mwenya, D, Mwansa, J, Sinyinza, F, Lishimpi, K, Nunn, A, Gillespie, S, Zumla, A, Chintu, C, Gibb, D

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects by Haberer, J, Cook, A, Walker, A, Ngambi, M, Ferrier, A, Mulenga, V, Kityo, C, Thomason, M, Kabamba, D, Chintu, C, Gibb, D, Bangsberg, DR

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children by Bienczak, A, Cook, A, Wiesner, L, Mulenga, V, Kityo, C, Kekitiinwa, A, Walker, A, Owen, A, Gibb, D, Burger, D, McIlleron, H, Denti, P

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa by Abongomera, G, Cook, A, Musiime, V, Chabala, C, Lamorde, M, Abach, J, Thomason, M, Mulenga, V, Kekitiinwa, A, Colebunders, R, Kityo, C, Walker, A, Gibb, D